Over 10 years, patients were followed in ADVANCE-ON, a post-trial follow-up study. No adverse or protective effect was seen whether their blood sugar was tightly controlled or not. However, strict blood pressure control did reduce cardiovascular and overall mortality during the trial.
Yann C. Klimentidis, PhD, of the University of Arizona Mel and Enid Zuckerman College of Public Health in Tucson, and colleagues wrote, “It has been well established that physical activity reduces type 2 diabetes risk. However, the extent of protection afforded by physical activity may differ according to genetic factors.”
Study results showed that patients on insulin pumps had a 29% reduction in mortality rate compared to patients on multiple daily insulin injection. Patients on insulin pumps had 43% lower risk of fatal cardiovascular disease compared to those on insulin injections.
Although the type 2 diabetes epidemic is commonly linked to being overweight or obese, excess weight isn’t the only factor driving the trend, new research suggests.
Patients with type 2 diabetes are at increased risk of cardiovascular disease. Fibrate may help decrease the risk of cardiovascular disease in women and could be an option for patients who cannot tolerate statins.
Swedish researchers have found that insulin pump users have better medical outcomes than those who use multiple daily injections. Also in recent news, The Juvenile Diabetes Research Foundation has awarded a $500,000 grant for research on an implantable encapsulation device that releases insulin-producing beta cells in the bloodstream of people with Type 1 diabetes.
Metformin, a drug commonly used to treat diabetes, may raise the risk of low levels of thyroid-stimulating hormone (TSH) among patients with an underactive thyroid, a new study suggests.
A study published in Nature this week provides evidence of a link between artificial sweeteners and diabetes, and the media is all over it. “Artificial sweeteners may disrupt body’s blood sugar controls,” wrote the New York Times; “Diet soda may alter our gut microbes and raise the risk of diabetes,” reported NPR.
This study tested the hypothesis that statin use increases the risk of diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, and gangrene of the foot in individuals with diabetes.
A paper just published in Nature bolsters that view. It provides a big dollop of evidence in support of an emerging idea that artificial sweeteners are not directly bad for people (humans cannot even digest most of them). Rather, they may be bad for the zillions of microbes that live in people’s guts—and this, in […]
A drug that mimics the action of a gut hormone combined with basal insulin is more effective at controlling blood sugar than other diabetes treatments, according to new research published in The Lancet.
In recent years, the medical community has become increasingly aware that taking statins can result in slightly higher glucose levels, and this can lead to a diagnosis of diabetes in a small but statistically significant number of people.
A series of papers published in The Lancet reveal that 15 percent of adult tuberculosis (TB) cases worldwide can be attributed to diabetes.
A 10-year analysis of patients with type 2 diabetes treated with pioglitazone (Actos) found no statistically significant increased risk of bladder cancer, either with any exposure or for long duration of use.
At 12 months, individuals on a low-carbohydrate diet had lost 5.3 kg, while those on a low-fat diet with similar caloric value had lost 1.8 kg, for a mean difference of -3.5 kg, or 7.7 lb, according to Lydia Bazzano, MD, PhD, of Tulane University in New Orleans, and colleagues.
Coffee increases the risk of prediabetes in young adults with hypertension who are slow caffeine metabolisers, according to results from the HARVEST study presented at ESC Congress by Dr Lucio Mos from Italy. People who drank more than three cups of coffee per day doubled their risk of prediabetes.
An international team of researchers conducted a trial as part of the multinational EDITION 1 study, comparing the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥42 units/day) plus mealtime insulin.
The results of the phase 3 trial – called the Durable Response Therapy Evaluation for Early or New-Onset Type 1 Diabetes, or DEFEND-1 – sends researchers back to the drawing board in an attempt to use otelixizumab, an antibody created specifically to treat type 1 diabetes and other autoimmune diseases, to help maintain insulin function.
Research has indicated that eating pistachios along with a high-glycemic meal may help lower after-meal blood sugar response, particularly in people with metabolic syndrome. Now, a small new study from Penn State University suggests that these nuts may also improve heart health in people who have Type 2 by reducing the body’s cardiovascular responses to […]
Diabetic peripheral neuropathy, which occurs in about half of all patients with type 2 diabetes, is underdiagnosed, and this is partly because physicians aren”t able to offer anything to treat the underlying cause of this condition, and the current treatments provided to these patients only treat the pain.